©The Author(s) 2025.
World J Gastrointest Oncol. Nov 15, 2025; 17(11): 111814
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111814
Published online Nov 15, 2025. doi: 10.4251/wjgo.v17.i11.111814
Figure 2 Literature search and screening process for prognostic risk factors associated with receiving transcatheter arterial chemoe mbolization in combination with lenvatinib for patients with unresectable hepatocellular carcinoma.
AFP: Alpha-fetoprotein; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer.
- Citation: Yu JH, Yu J, Yu JX, Yang LF, Yan D, Liu Y, Xian JR, Yi PS. Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib. World J Gastrointest Oncol 2025; 17(11): 111814
- URL: https://www.wjgnet.com/1948-5204/full/v17/i11/111814.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i11.111814